kabutan

Chordia Therapeutics Inc.(190A) Summary

190A
TSE Growth
Chordia Therapeutics Inc.
150
JPY
-5
(-3.23%)
Apr 30, 10:16 am JST
0.93
USD
Apr 29, 9:16 pm EDT
Result
PTS
outside of trading hours
149.8
Apr 30, 10:16 am JST
Summary Chart Historical News Financial Result
PER
PBR
4.90
Yield
ー%
Margin Trading Ratio
531.43
Stock Price
Apr 30, 2026
Opening Apr 30, 9:00 am
155 JPY 0.96 USD
Previous Close Apr 28
155 JPY 0.97 USD
High Apr 30, 9:00 am
155 JPY 0.96 USD
Low Apr 30, 9:20 am
147 JPY 0.91 USD
Volume
403,400
Trading Value
0.06B JPY 0.38M USD
VWAP
149.06 JPY 0.93 USD
Minimum Trading Value
15,000 JPY 93 USD
Market Cap
0.01T JPY 0.07B USD
Number of Trades
135
Liquidity & Number of Trades
As of Apr 30, 2026
Liquidity
Slightly High
1-Year Average
453
1-Year High Feb 27, 2026
11,759
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 0 6,243,600
Apr 17, 2026 500 5,854,900 11709.80
Apr 10, 2026 0 6,071,600
Apr 3, 2026 0 5,950,100
Mar 27, 2026 0 5,604,000
Company Profile
Chordia Therapeutics Inc. engages in the development of cancer therapeutics targeting RNA regulation stress.
Sector
Pharmaceuticals
Chordia Therapeutics Inc. is a drug discovery venture company specializing in the research and development of novel anti-cancer drugs targeting RNA regulation stress. The company has multiple pipelines including CLK inhibitors, MALT1 inhibitors, and CDK12 inhibitors, aiming to create groundbreaking first-in-class pharmaceuticals. Clinical trials are currently underway for acute myeloid leukemia, ovarian cancer, and other indications. Chordia Therapeutics actively promotes collaborative research and licensing partnerships with universities, public institutions, and pharmaceutical companies to achieve efficient drug discovery operations. The company is also expanding its partnering strategy, as exemplified by the licensing agreement for MALT1 inhibitors with Ono Pharmaceutical Co., Ltd.